Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Основные принципы терапии НПВП: эффективность, безопасность, индивидуальный подход
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Jüni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324 (7349): 1287-8.
2. Singh G, Fort JG, Goldstein JL et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119 (3): 255–66.
3. Laine L, Curtis SP, Langman M et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135: 1517–25.
4. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004; 117 (2), 100–106.
5. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086. doi: 10.1136/bmj.c7086.
6. Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.//Rheumatology (Oxford). 2003 Nov;42(11):1354-64.
7. Ryn J van, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G, Trummlitz G, Pairet M Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004; 44 (7), 777–784.
8. Winkelmayer WC; Walker SS; Mogun H; Solomon DH Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 2008; 121 (12), 1092–1098.
2. Singh G, Fort JG, Goldstein JL et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119 (3): 255–66.
3. Laine L, Curtis SP, Langman M et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135: 1517–25.
4. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004; 117 (2), 100–106.
5. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086. doi: 10.1136/bmj.c7086.
6. Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.//Rheumatology (Oxford). 2003 Nov;42(11):1354-64.
7. Ryn J van, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G, Trummlitz G, Pairet M Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004; 44 (7), 777–784.
8. Winkelmayer WC; Walker SS; Mogun H; Solomon DH Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 2008; 121 (12), 1092–1098.
Авторы
Е.С.Акарачкова1, И.А.Зайцева2
1. Отдел патологии вегетативной нервной системы НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова;
2. Кафедра нелекарственных методов лечения и клинической физиологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова
1. Отдел патологии вегетативной нервной системы НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова;
2. Кафедра нелекарственных методов лечения и клинической физиологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.